ReviewCurrent pharmaceutical design2009
Rho kinase: an important mediator of atherosclerosis and vascular disease.
Review in Current pharmaceutical design, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 107 citations in OpenAlex.
- Chitosan Oligosaccharides Modulate Macrophage Inflammatory Signaling: Molecular Docking and Transcriptomic Evidence.International journal of molecular sciences · 2026Article
- Review
- Hyperuricaemia-Induced Hypertension in Rats by Regulating the RhoA/ROCK Pathway.Kidney & blood pressure research · 2026Article
- How Protein Depletion Balances Thrombosis and Bleeding Risk in the Context of Platelet's Activatory and Negative Signaling.International journal of molecular sciences · 2024Review
- Direct active Fyn-paxillin interaction regulates vascular smooth muscle cell migration.Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi · 2023Review
- Executable models of immune signaling pathways in HIV-associated atherosclerosis.NPJ systems biology and applications · 2022Article
- [Rho kinase inhibitors as new local therapy option in primary open angle glaucoma].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021Review
- Myosin Phosphatase Is Implicated in the Control of THP-1 Monocyte to Macrophage Differentiation.International journal of molecular sciences · 2021Article
- Methyl Ferulic Acid Attenuates Human Cardiac Fibroblasts Differentiation and Myocardial Fibrosis by Suppressing pRB-E2F1/CCNE2 and RhoA/ROCK2 Pathway.Frontiers in pharmacology · 2021Article
- Role of Macrophages and RhoA Pathway in Atherosclerosis.International journal of molecular sciences · 2020Review
- Inhibition of Rho-kinase is involved in the therapeutic effects of atorvastatin in heart ischemia/reperfusion.Experimental and therapeutic medicine · 2020Article
- Reactive oxygen species in cardiovascular health and disease: special references to nitric oxide, hydrogen peroxide, and Rho-kinase.Journal of clinical biochemistry and nutrition · 2020Review
- KRIT1 Deficiency Promotes Aortic Endothelial Dysfunction.International journal of molecular sciences · 2019Article
- RhoGTPase in Vascular Disease.Cells · 2019Review
- Druggable targets in the Rho pathway and their promise for therapeutic control of blood pressure.Pharmacology & therapeutics · 2019Review
- Gene expression profile analysis of the progression of carotid atherosclerotic plaques.Molecular medicine reports · 2018Article
- Tumor necrosis factor-α levels and non-surgical bleeding in continuous-flow left ventricular assist devices.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2018Article
- Fasudil improves endothelial dysfunction in rats exposed to chronic intermittent hypoxia through RhoA/ROCK/NFATc3 pathway.PloS one · 2018Article
- In Development-A New Paradigm for Understanding Vascular Disease.Journal of cardiovascular pharmacology · 2017Review
- Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers.Cell death & disease · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Atherosclerosis is a complex inflammatory process characterized by the cross-talk between excessive inflammation and lipid accumulation. In the past few years, compelling evidence suggests that statins can decrease vascular inflammation and attenuate the development of atherosclerosis through their so-called "pleiotropic effects". These cholesterol-independent effects are predominantly due to their ability to inhibit isoprenoid synthesis. In particular, inhibition of geranylgeranylpyrophosphate synthesis leads to inhibition of Rho and its downstream target, Rho-kinase (ROCK). Thus, one of the beneficial effects of statin therapy could be due to inhibitory effects on ROCK. ROCK is involved in mediating diverse cellular functions such as smooth muscle contraction, cell migration and proliferation. While increased ROCK activity is associated with endothelial dysfunction, cerebral ischemia, coronary vasospasms and metabolic syndrome, the inhibition of ROCK by statins or selective ROCK inhibitors leads to up-regulation of endothelial nitric oxide synthase (eNOS), decreased vascular inflammation, and reduced atherosclerotic plaque formation. This review will focus on the impact of ROCK in cardiovascular disease and its contributory role to vascular inflammation and the atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.